Theravance Biopharma reported their Q1 2022 financial results, highlighting their execution against the business plan and remaining on track to become sustainably cash-flow positive by the second half of 2022. YUPELRI's hospital sales performance and market share gains were noted. The company plans to define a path forward for ampreloxetine through discussions with regulators and strategic partners.